Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge
The Motley Fool
by newsfeedback@fool.com (Adé Hennis)February 16, 2026
Maze Therapeutics has been flourishing as a stock and in its operations, which is one of the reasons its Chief Medical Officer's recent share sale shouldn't raise concerns for investors.
Verticals
financeinvesting
Originally published on The Motley Fool on 2/16/2026